Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$4.07 USD
+0.28 (7.39%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.06 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.07 USD
+0.28 (7.39%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.06 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -15.79% and 37.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocuphire Pharma (OCUP) delivered earnings and revenue surprises of -3.45% and 38.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -550% and 6.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 31.94% and 20.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
by Zacks Equity Research
Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 75.68% and 6.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
by Zacks Equity Research
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Centene (CNC) and Absci Corporation (ABSI) have performed compared to their sector so far this year.
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -13.33% and 87.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 19.05% and 0.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -8.33% and 41.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Joint Corp. (JYNT) Misses Q4 Earnings Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -42.86% and 1.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?